James Noble
2017
In 2017, James Noble earned a total compensation of $1.7M as Chief Executive Officer at Adaptimmune Therapeutics, a 13% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $247,767 |
|---|---|
| Option Awards | $849,927 |
| Salary | $550,591 |
| Other | $28,669 |
| Total | $1,676,954 |
Noble received $849.9K in option awards, accounting for 51% of the total pay in 2017.
Noble also received $247.8K in non-equity incentive plan, $550.6K in salary and $28.7K in other compensation.
Rankings
In 2017, James Noble's compensation ranked 6,404th out of 14,666 executives tracked by ExecPay. In other words, Noble earned more than 56.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,404 out of 14,666 | 56th |
Division Manufacturing | 2,359 out of 5,772 | 59th |
Major group Chemicals And Allied Products | 751 out of 2,075 | 64th |
Industry group Drugs | 580 out of 1,731 | 67th |
Industry Biological Products, Except Diagnostic Substances | 105 out of 313 | 67th |
Source: SEC filing on April 27, 2018.
Noble's colleagues
We found four more compensation records of executives who worked with James Noble at Adaptimmune Therapeutics in 2017.